drug
fingolimod ODT
Marketedupdated 4mo agoby Cycle Pharmaceuticals Ltd
Approvedcommunity read0 votes
indications
investigational
Multiple Sclerosis
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 19, 2036
~9.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jan 19, 2036method-of-use (U-3268)US 10555902
- Jan 19, 2036method-of-use (U-3493)US 10555902
- Jan 19, 2036formulationUS 10925829
- Jan 19, 2036formulationUS 10925829
- Jan 19, 2036formulationUS 9925138
- Jan 19, 2036formulationUS 9925138
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that